VKTX

Viking Therapeutics Inc

VKTX, USA

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

https://www.vikingtherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VKTX
stock
VKTX

Treasury Yields: How resilient is VKTX stock in market downturns - Wall Street Watch & Long-Term Growth Portfolio Plans moha.gov.vn

Read more →
VKTX
stock
VKTX

Published on: 2025-12-13 18:35:30 moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$93.3889

Analyst Picks

Strong Buy

10

Buy

7

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

5.84

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-12.73 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-12.28 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.04

Low 1

High 0.3

Investors

* Institutions hold a combined 66.72% of the total shares of Viking Therapeutics Inc

1.

Vanguard Group Inc

(9.0379%)

since

2025/06/30

2.

FMR Inc

(8.7348%)

since

2025/06/30

3.

BlackRock Inc

(4.8357%)

since

2025/06/30

4.

State Street Corp

(3.3578%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(3.0023%)

since

2025/07/31

6.

Morgan Stanley - Brokerage Accounts

(2.8883%)

since

2025/06/30

7.

JPMorgan Chase & Co

(2.347%)

since

2025/06/30

8.

Vanguard Small Cap Index

(2.3024%)

since

2025/07/31

9.

Susquehanna International Group, LLP

(1.8379%)

since

2025/06/30

10.

Geode Capital Management, LLC

(1.7104%)

since

2025/06/30

11.

SPDR® S&P Biotech ETF

(1.7096%)

since

2025/08/31

12.

Pictet Asset Manangement SA

(1.7047%)

since

2025/06/30

13.

NORGES BANK

(1.5721%)

since

2025/06/30

14.

Ameriprise Financial Inc

(1.3129%)

since

2025/06/30

15.

Vanguard Small Cap Growth Index Inv

(1.2841%)

since

2025/07/31

16.

BRAIDWELL LP

(1.2785%)

since

2025/06/30

17.

Two Sigma Investments LLC

(1.1684%)

since

2025/06/30

18.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0731%)

since

2025/07/31

19.

Fidelity Select Health Care

(1.0494%)

since

2025/07/31

20.

JPM US Mid Cap Growth-Composite

(0.9707%)

since

2025/06/30

21.

Two Sigma Advisers, LLC

(0.9706%)

since

2025/06/30

22.

JPMorgan Mid Cap Growth I

(0.9676%)

since

2025/07/31

23.

Fidelity Advisor Growth Opps M

(0.9446%)

since

2025/07/31

24.

Pictet-Biotech P USD

(0.8934%)

since

2025/05/31

25.

UBS Group AG

(0.8462%)

since

2025/06/30

26.

Millennium Management LLC

(0.8377%)

since

2025/06/30

27.

Citadel Advisors Llc

(0.7764%)

since

2025/06/30

28.

Citigroup Inc

(0.7685%)

since

2025/06/30

29.

Jane Street Group LLC

(0.6511%)

since

2025/06/30

30.

Charles Schwab Investment Management Inc

(0.6469%)

since

2025/06/30

31.

Pictet-Global Megatrend Sel I USD

(0.6106%)

since

2025/05/31

32.

Fidelity Advisor Health Care I

(0.5958%)

since

2025/07/31

33.

CT (Lux) American Smaller Com 9U USD

(0.5908%)

since

2025/07/31

34.

Strategic Advisers Fidelity US TtlStk

(0.5773%)

since

2025/07/31

35.

Fidelity Advisor Biotechnology I

(0.5387%)

since

2025/07/31

36.

Fidelity Extended Market Index

(0.537%)

since

2025/07/31

37.

Fidelity Blue Chip Growth

(0.5366%)

since

2025/07/31

38.

Schwab US Small-Cap ETF™

(0.475%)

since

2025/08/30

39.

JPM US Mid Cap Growth-MA

(0.404%)

since

2025/06/30

40.

Fidelity Select Biotechnology

(0.3753%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.89

Latest Release

Date

2025-09-30

EPS Actual

-0.81

EPS Estimate

-0.67

EPS Difference

-0.14

Surprise Percent

-20.8955%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(6)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.